A double-blind, randomized, placebo-controlled study assessing the efficacy and tolerability of desvenlafaxine 10 and 50 mg/day in adult outpatients with major depressive disorder
Open accessThe DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
BACKGROUND: In an effort to establish the lowest effective dose of desvenlafaxine (administered as desvenlafaxine succinate), we assessed the efficacy, safety, and tolerability of 10- and 50-mg/day desvenlafaxine vs placebo for the treatment of major depressive disorder. METHODS: Adult outpatients with DSM-IV-defined major depressive disorder and a 17-item Hamilton Rating Scale for Depression (HAM-D(17)) total score ≥20 were randomly assigned to receive placebo or desvenlafaxine (10 or 50 mg/day) after a 6- to 14-day single-blind placebo lead-in period in an 8-week, phase 3, fixed-dose trial. The primary efficacy measure was change from baseline in the HAM-D(17) score analyzed using analysis of covariance. Efficacy analyses were conducted with the intent-to-treat population, using the last observation carried forward. RESULTS: The intent-to-treat population included 673 patients. Change from baseline to final evaluation in adjusted HAM-D(17) total scores was not significantly different comparing desvenlafaxine 10 mg/day (-9.28) and desvenlafaxine 50 mg/day (-8.92) with placebo (-8.42). There were no differences among treatment groups in the rates of treatment response or remission. Discontinuations due to adverse events occurred in 1.8%, 0.9%, and 1.8% of patients in the placebo and desvenlafaxine 10- and 50-mg/day groups, respectively. Overall rates of treatment-emergent adverse events with both doses were similar to placebo. CONCLUSIONS: Both doses of desvenlafaxine failed to separate from placebo. However, in a companion study reported separately, desvenlafaxine 50 mg, but not 25 mg, separated from placebo. Taken together, these studies suggest that 50 mg is the minimum effective dose of desvenlafaxine for the treatment of major depressive disorder. CLINICALTRIALS.GOV IDENTIFIER: NCT00863798 http://clinicaltrials.gov/ct2/show/NCT00863798?term=00863798&rank=1.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Antidepressant Drug Effects and Depression Severity: A Patient-Level Meta-analysis
Fournier, J. C., DeRubeis, R. J., Hollon, S. D., Dimidjian, S., Amsterdam, J. D., Shelton, R. C., & Fawcett, J. (2010) · JAMA · doi:10.1001/jama.2009.1943 · Cited by 2,009
Sheehan, D. V., Harnett-Sheehan, K., Spann, M. E., Thompson, H. F., & Prakash, A. (2011) · International Clinical Psychopharmacology · doi:10.1097/yic.0b013e328341bb5f · Cited by 124
Rickels, K., Montgomery, S. A., Tourian, K. A., Guelfi, J. D., Pitrosky, B., Padmanabhan, S. K., Germain, J.-M., Leurent, C., & Brisard, C. (2010) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e3181c94c4d · Cited by 33 · cited 1×
“The efficacy and safety of desvenlafaxine at doses of 50, 100, 200, and 400 mg/day for the treatment of MDD has been evaluated in short-term, randomized, double-blind, placebocontrolled trials in adult outpatients with MDD [5-12].”
Method
Research works printed but not linked: 17
- Gelenberg AJ: The prevalence and impact of depression. J Clin Psychiatr. 2010, 71: e06-10.4088/JCP.8001tx17c. · DOI · Paper page
- Kessler RC, Berglund P, Demler O, Jin R, Merikangas KR, Walters EE: Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry. 2005, 62: 593-602. 10.1001/archpsyc.62.6.593. · DOI · Paper page
- American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders DSM-IV. 1994, Washington, DC: American Psychiatric Association
- Liebowitz MR, Yeung PP, Entsuah R: A randomized, double-blind, placebo-controlled trial of desvenlafaxine succinate in adult outpatients with major depressive disorder. J Clin Psychiatr. 2007, 68: 1663-1672. 10.4088/JCP.v68n1105. · DOI · Paper page
- DeMartinis NA, Yeung PP, Entsuah R, Manley AL: A double-blind, placebo-controlled study of the efficacy and safety of desvenlafaxine succinate in the treatment of major depressive disorder. J Clin Psychiatr. 2007, 68: 677-688. 10.4088/JCP.v68n0504. · DOI · Paper page
- Septien-Velez L, Pitrosky B, Padmanabhan SK, Germain JM, Tourian KA: A randomized, double-blind, placebo-controlled trial of desvenlafaxine succinate in the treatment of major depressive disorder. Int Clin Psychopharmacol. 2007, 22: 338-347. 10.1097/YIC.0b013e3281e2c84b. · DOI · Paper page
- Boyer P, Montgomery S, Lepola U, Germain JM, Brisard C, Ganguly R, Padmanabhan SK, Tourian KA: Efficacy, safety, and tolerability of fixed-dose desvenlafaxine 50 and 100 mg/day for major depressive disorder in a placebo-controlled trial. Int Clin Psychopharmacol. 2008, 23: 243-253. 10.1097/YIC.0b013e32830cebed. · DOI · Paper page
- Liebowitz MR, Manley AL, Padmanabhan SK, Ganguly R, Tummala R, Tourian KA: Efficacy, safety, and tolerability of desvenlafaxine 50 mg/day and 100 mg/day in outpatients with major depressive disorder. Curr Med Res Opin. 2008, 24: 1877-1890. 10.1185/03007990802161923. · DOI · Paper page
- Tourian KA, Padmanabhan SK, Groark J, Brisard C, Farrington D: Desvenlafaxine 50 and 100 mg/d in the treatment of major depressive disorder: an 8-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group trial and a post hoc pooled analysis of three studies. Clin Ther. 2009, 31 (Pt 1): 1405-1423. · DOI
- Feiger AD, Tourian KA, Rosas GR, Padmanabhan SK: A placebo-controlled study evaluating the efficacy and safety of flexible-dose desvenlafaxine treatment in outpatients with major depressive disorder. CNS Spectr. 2009, 14: 41-50. · DOI · Paper page
- Iwata N, Tourian KA, Hwang E, Mele L, Vialet C, for the Study 3359 Investigators: Efficacy and safety of desvenlafaxine 25 and 50 mg/d in a randomized, placebo-controlled study of depressed outpatients. J Psychiatr Pract. 2013, 19: 5-14. 10.1097/01.pra.0000426323.59698.64. · DOI · Paper page
- Guy W: Clinical Global Impressions. ECDEU Assessment Manual for Psychopharmacology. 1976, Rockville, MD: US Department of Health, Education, and Welfare, 217-222.
- Montgomery SA, Asberg M: A new depression scale designed to be sensitive to change. Br J Psychiatry. 1979, 134: 382-389. 10.1192/bjp.134.4.382. · DOI · Paper page
- Khan A, Detke M, Khan SR, Mallinckrodt C: Placebo response and antidepressant clinical trial outcome. J Nerv Ment Dis. 2003, 191: 211-218.
- Moller HJ: Rating depressed patients: observer- vs self-assessment. Eur Psychiatr. 2000, 15: 160-172. 10.1016/S0924-9338(00)00229-7. · DOI · Paper page
- Bech P: Rating scales in depression: limitations and pitfalls. Dialogues Clin Neurosci. 2006, 8: 207-215. · DOI · Paper page
- Demyttenaere K, Desaiah D, Petit C, Croenlein J, Brecht S: Patient-assessed versus physician-assessed disease severity and outcome in patients with nonspecific pain associated with major depressive disorder. Prim Care Companion J Clin Psychiatr. 2009, 11: 8-15. 10.4088/PCC.08m00670. · DOI
Cited by
Meta-analysis: Risk of dry mouth with second generation antidepressants
Cappetta, K., Beyer, C., Johnson, J. A., & Bloch, M. H. (2018) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2017.12.012 · Cited by 49
Grigolon, R. B., Trevizol, A. P., Gerchman, F., Bambokian, A. D., Magee, T., McIntyre, R. S., Gomes, F. A., Brietzke, E., & Mansur, R. B. (2021) · Journal of Affective Disorders · doi:10.1016/j.jad.2021.03.032 · Cited by 35
Lee, S.-H., Jeon, S. W., Shin, C., Pae, C.-U., Patkar, A. A., Masand, P. S., An, H., & Han, C. (2022) · Psychiatry Investigation · doi:10.30773/pi.2021.0368 · Cited by 12
Zimmerman, M., Balling, C., Chelminski, I., & Dalrymple, K. (2020) · Journal of Affective Disorders · doi:10.1016/j.jad.2019.09.012 · Cited by 10
Metadata
- Authors
- for the Study 3362 Investigators, Liebowitz, M. R., Tourian, K. A., Hwang, E., & Mele, L.
- Venue
- BMC Psychiatry
- Published
- 2013-03-22
- Volume
- 13
- Issue
- 1
- Pages
- 94-94
- ISSN
- 1471-244X (ISSN-L)
- OpenAlex
- W1995734286
- Cited by
- 49
- References
- 3
- FWCI
- 3.91
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A double-blind, randomized, placebo-controlled study assessing the efficacy and tolerability of desvenlafaxine 10 and 50 mg/day in adult outpatients with major depressive disorder. https://app.cochat.ai/papers/10.1186/1471-244x-13-94
- The paper
- for the Study 3362 Investigators, Liebowitz, M. R., Tourian, K. A., Hwang, E., & Mele, L. (2013). A double-blind, randomized, placebo-controlled study assessing the efficacy and tolerability of desvenlafaxine 10 and 50 mg/day in adult outpatients with major depressive disorder. BMC Psychiatry. https://doi.org/10.1186/1471-244x-13-94
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.